Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Operating Leases (2022 - 2025)

Historic Operating Leases for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $40.5 million.

  • Zentalis Pharmaceuticals' Operating Leases fell 649.24% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year decrease of 649.24%. This contributed to the annual value of $39.6 million for FY2024, which is 828.04% down from last year.
  • As of Q3 2025, Zentalis Pharmaceuticals' Operating Leases stood at $40.5 million, which was down 649.24% from $41.3 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Operating Leases high stood at $47.0 million for Q1 2023, and its period low was $39.6 million during Q4 2024.
  • Over the past 4 years, Zentalis Pharmaceuticals' median Operating Leases value was $43.6 million (recorded in 2024), while the average stood at $43.6 million.
  • The largest annual percentage gain for Zentalis Pharmaceuticals' Operating Leases in the last 5 years was 353.69% (2024), contrasted with its biggest fall of 828.04% (2024).
  • Zentalis Pharmaceuticals' Operating Leases (Quarter) stood at $45.2 million in 2022, then dropped by 4.46% to $43.2 million in 2023, then dropped by 8.28% to $39.6 million in 2024, then increased by 2.22% to $40.5 million in 2025.
  • Its Operating Leases stands at $40.5 million for Q3 2025, versus $41.3 million for Q2 2025 and $42.2 million for Q1 2025.